Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.76 |
| ▸ | PGR | P06401 | 3/20 | 0.76 |
| ▸ | AR | P10275 | 2/20 | 0.76 |
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532598 | 0.90 | NR3C1 (0.80) | NR3C1PGRARTRPV1 | |
| SCHEMBL3535256 | 0.89 | NR3C1 (0.76) | NR3C1PGRARTRPV1 | |
| SCHEMBL3532208 | 0.87 | NR3C1 (0.73) | NR3C1PGRARTRPV1 | |
| SCHEMBL3532426 | 0.87 | NR3C1 (0.73) | NR3C1PGRARTRPV1OPRM1 | |
| SCHEMBL3532406 | 0.86 | NR3C1 (1.00) | NR3C1PGRARTRPV1 | |
| SCHEMBL3540965 | 0.85 | NR3C1 (0.82) | NR3C1PGRARTRPV1 | |
| SCHEMBL3534542 | 0.85 | NR3C1 (0.70) | NR3C1PGRARTRPV1 | |
| SCHEMBL3535474 | 0.85 | NR3C1 (0.72) | NR3C1PGRARTRPV1 | |
| SCHEMBL3532778 | 0.84 | NR3C1 (0.79) | NR3C1PGRARTRPV1 | |
| SCHEMBL3540670 | 0.84 | NR3C1 (0.71) | NR3C1PGRARTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659297-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | Bayer Schering Pharma, AG (DE) | 2010-02-09 | — | — | US | disclosed |
| EP-1670458-B1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| US-20050272823-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272823-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | DHPS, TNF, PTGES | NR3C1 1000/4885PGR 3505/4885AR 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.